Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Emergent Biosolutions (NY: EBS ) 9.190 +0.720 (+8.50%) Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Emergent Biosolutions < Previous 1 2 3 4 5 6 7 8 9 10 Next > What's Going On With Emergent BioSolutions Stock Wednesday? October 02, 2024 Emergent BioSolutions stock is trading higher after the company announced the closing of a $100 million asset-backed revolving loan facility. Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session September 26, 2024 Via Benzinga Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines September 25, 2024 Emergent BioSolutions secures $400M in orders for smallpox and mpox products, receives FDA approval for ACAM2000's expanded use, and updates its 2024 revenue forecast while beating Q2 sales estimates. Via Benzinga Exposures Product Safety Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session September 09, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session September 02, 2024 Via Benzinga (EBS) - Analyzing Emergent BioSolutions's Short Interest August 20, 2024 Via Benzinga 7 Analysts Assess Emergent BioSolutions: What You Need To Know August 16, 2024 Via Benzinga Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine August 30, 2024 Emergent BioSolutions stock jumped early Friday. Via Investor's Business Daily Exposures Product Safety Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection August 30, 2024 The FDA has approved Emergent BioSolutions' supplemental Biologics License Application for ACAM2000 to include the prevention of mpox disease in high-risk individuals, with the approval based on human... Via Benzinga Exposures Product Safety Why MongoDB Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket August 30, 2024 Via Benzinga WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped' August 26, 2024 To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan. Via Benzinga Macy's Reports Weak Sales, Joins JD.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session August 21, 2024 Via Benzinga 3 Promising Vaccine Stocks To Watch In The Event Of A Mpox Surge August 19, 2024 Mpox rerun is making these stocks soar. But a non-vaccine approach could yield greater gains. Via Talk Markets Why Emergent BioSolutions Stock Is Skyrocketing Today August 16, 2024 Concerns about the mpox outbreak are causing Emergent BioSolutions' shares to jump. Via The Motley Fool H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday August 16, 2024 Via Benzinga Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket August 16, 2024 Via Benzinga Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday: What's Going On? August 15, 2024 Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa. Via Benzinga Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session August 15, 2024 Via Benzinga WHO Declares Mpox Public Health Emergency: 'Coordinated International Response Essential' To Halt Outbreak August 14, 2024 A public health emergency for mpox in Africa saw vaccine stocks jump Wednesday. A look at the stocks and what's next for fighting the virus. Via Benzinga Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks August 07, 2024 Emergent BioSolutions reported Q2 2024 sales of $254.7 million, beating estimates but showing a 25% decline year-over-year. Despite a significant adjusted EPS loss and mixed performance across product... Via Benzinga Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session August 07, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday August 07, 2024 Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! Via InvestorPlace Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket August 07, 2024 Via Benzinga Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript August 07, 2024 EBS earnings call for the period ending June 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial 8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803% August 01, 2024 Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%. Via Benzinga How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings July 18, 2024 American Express offers an annual dividend yield of 1.12%, or $2.80 a year. How can investors pocket a regular $500 monthly? Via Benzinga How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings July 16, 2024 JNJ to release 2Q financial results on July 17. Expected earnings $2.70/share, revenue $22.29B. Investors eye 3.32% dividend yield for gains. Via Benzinga Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs July 09, 2024 Johnson & Johnson is set to release its Q2 2024 earnings on July 17. Analysts estimate $22.29 billion in sales and an EPS of $2.71. Via Benzinga Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing July 09, 2024 Emergent BioSolutions and Janssen Pharmaceuticals settle disputes over SARS-CoV-2 vaccine manufacturing with a $50 million agreement, resolving all related claims and arbitration. Via Benzinga Exposures COVID-19 Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? July 02, 2024 Emergent BioSolutions has secured over $250 million in contract modifications from the ASPR at the U.S. Department of Health and Human Services. The funding ensures the supply of critical medical... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.